Thank you, Tyler. Revenue growth and adjusted operating margin again outpaced our expectations. By segment, financial ...
Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy January 26, ...